EE178 CEA of Once-Weekly Subcutaneous Semaglutide Versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.427
https://www.valueinhealthjournal.com/article/S1098-3015(22)00628-3/fulltext
Title :
EE178 CEA of Once-Weekly Subcutaneous Semaglutide Versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00628-3&doi=10.1016/j.jval.2022.04.427
First page :
Section Title :
Open access? :
No
Section Order :
10376